Lineage Cell Therapeutics, Inc.
LCTX
$0.50
-$0.02-3.85%
| Weiss Ratings | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.94 | |||
| Price History | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.82% | |||
| 30-Day Total Return | -27.48% | |||
| 60-Day Total Return | 0.62% | |||
| 90-Day Total Return | -40.38% | |||
| Year to Date Total Return | -2.91% | |||
| 1-Year Total Return | -57.27% | |||
| 2-Year Total Return | -63.77% | |||
| 3-Year Total Return | -64.54% | |||
| 5-Year Total Return | -16.68% | |||
| 52-Week High % Change | -68.94% | |||
| 52-Week Low % Change | 3.95% | |||
| Price | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.61 | |||
| 52-Week Low Price | $0.48 | |||
| 52-Week Low Price (Date) | Dec 17, 2024 | |||
| 52-Week High Price (Date) | Mar 28, 2024 | |||
| Valuation | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 114.18M | |||
| Enterprise Value | 67.52M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.10 | |||
| Earnings Per Share Growth | -22.83% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 12.66 | |||
| Price/Book (Q) | 1.41 | |||
| Enterprise Value/Revenue (TTM) | 7.11 | |||
| Price | $0.50 | |||
| Enterprise Value/EBITDA (TTM) | -3.24 | |||
| Enterprise Value/EBIT | -3.14 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 240.19M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 442 287 8990 | |||
| Address | 2173 Salk Avenue Carlsbad, CA 92008 | |||
| Website | www.lineagecell.com | |||
| Country | United States | |||
| Year Founded | 1990 | |||
| Profitability | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -226.10% | |||
| Profit Margin | -195.90% | |||
| Management Effectiveness | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -12.53% | |||
| Return on Equity | -- | |||
| Income Statement | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 9.50M | |||
| Total Revenue (TTM) | 9.50M | |||
| Revenue Per Share | $0.04 | |||
| Gross Profit (TTM) | -3.31M | |||
| EBITDA (TTM) | -20.87M | |||
| EBIT (TTM) | -21.48M | |||
| Net Income (TTM) | -18.61M | |||
| Net Income Avl. to Common (TTM) | -18.61M | |||
| Total Revenue Growth (Q YOY) | 37.36% | |||
| Earnings Growth (Q YOY) | 31.06% | |||
| EPS Diluted (TTM) | -0.10 | |||
| EPS Diluted Growth (Q YOY) | 50.18% | |||
| Balance Sheet | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 47.81M | |||
| Cash Per Share (Q) | $0.20 | |||
| Total Current Assets (Q) | 51.00M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 77.01M | |||
| Current Ratio (Q) | 3.649 | |||
| Book Value Per Share (Q) | $0.36 | |||
| Total Assets (Q) | 113.22M | |||
| Total Current Liabilities (Q) | 13.98M | |||
| Total Debt (Q) | 2.51M | |||
| Total Liabilities (Q) | 36.21M | |||
| Total Common Equity (Q) | 78.38M | |||
| Cash Flow | LCTX - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -2.31M | |||
| Cash from Financing (TTM) | 35.86M | |||
| Net Change in Cash (TTM) | 10.36M | |||
| Levered Free Cash Flow (TTM) | -12.80M | |||
| Cash from Operations (TTM) | -23.09M | |||
